Insulet Corporation
Financials
Valuation Metrics
Insulet Corporation's Market Cap is $11.75B. At end of 2025 it was $20.00B. Ranked #871 of 3,111 in US market (top 28%), #272 of 1,445 on NASDAQ (top 19%), #56 of 206 in Health Care Equipment & Services (top 27%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $11.75B | US#871/3,111 Sec#56/206 |
| Revenue | $2.90B | US#1,261/3,111 Sec#74/206 |
| Net Income | $303M | US#1,065/3,111 Sec#54/206 |
| Total Assets | $2.99B | US#1,807/3,111 Sec#86/206 |
| Net Assets | $1.30B | US#1,581/3,111 Sec#83/206 |
| Employees | 5,400 | US#819/3,111 Sec#71/206 |
| Value | ||
| P/E | 38.82x | US#1,678/3,111 Sec#74/206 |
| P/B | 9.02x | US#2,563/3,111 Sec#171/206 |
| PEG | 0.25x | US#357/3,111 Sec#10/206 |
| P/S | 4.05x | US#2,077/3,111 Sec#143/206 |
| EV/EBITDA | 21.26x | US#1,900/3,111 Sec#89/206 |
| FCF Yield | 3.51% | US#1,626/3,111 Sec#94/206 |
| Profitability | ||
| ROE | 23.25% | US#457/3,111 Sec#22/206 |
| ROA | 10.14% | US#438/3,111 Sec#26/206 |
| Op. Margin | 17.48% | US#1,080/3,111 Sec#37/206 |
| Revenue Growth | 33.87% | US#448/3,111 Sec#27/206 |
| Earnings Growth | 157.34% | US#243/3,111 Sec#7/206 |
| Financial Health | ||
| Debt Ratio | 129.33% | US#1,337/3,111 Sec#128/206 |
| Total Debt | $948M | US#1,537/3,111 Sec#81/206 |
| FCF | $412M | US#956/3,111 Sec#56/206 |
| Cash | $480M | US#1,098/3,111 Sec#64/206 |
| Current Ratio | 2.49x | US#997/3,111 Sec#99/206 |
| Net Debt/EBITDA | 0.81x | US#926/3,111 Sec#54/206 |
| Performance | ||
| 1Y Return | -40.44% | US#2,886/3,111 Sec#188/206 |
| 1M Return | 3.17% | US#1,054/3,111 Sec#87/206 |
| From 52W High | -52.18% | US#2,821/3,111 Sec#183/206 |
| 1Y MDD | -60.61% | US#2,735/3,111 Sec#176/206 |
| Trading | ||
| Volume | 1,383,089 shares | US#1,333/3,111 Sec#84/206 |
| Trading Value | $234M | US#550/3,111 Sec#43/206 |
| Per Share | ||
| EPS | $3.51 | US#881/3,111 Sec#53/206 |
| BPS | $21.53 | US#1,135/3,111 Sec#67/206 |
Company Info
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.